Education
About Us
Working with TipRanks
Follow Us
Annexon Biosciences (ANNX)
NASDAQ:ANNX
Tanruprubart
Guillain-Barre Syndrome
Phase III
Not Yet Recruiting
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
Jun 06, 2025
―
Sham Administration, Anx007
Geographic Atrophy
Phase III
Recruiting
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA)
Jul 15, 2024
―
Anx1502
Healthy
Phase I
Completed
Dose Study of ANX1502 in Healthy Volunteers
Aug 28, 2022
―
Anx005
Guillain-Barre Syndrome
Phase III
Completed
Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome
Jan 06, 2021
―
Anx005
Amyotrophic Lateral Sclerosis
Phase II
Completed
Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)
Sep 23, 2020
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Annexon Biosciences (ANNX) have in its pipeline
ANNX is currently developing the following drugs: Tanruprubart, Sham Administration, Anx007, Anx1502. These drug candidates are in various stages of clinical development as the company works toward FDA approval.